SEC Filings
4D Molecular Therapeutics Has $375 Million To Support Its Retinal Drug Trials
Management expects cash and collaboration payments to cover operations at least into the second half of 2028, beyond planned 2027 trial results.
4D Molecular Therapeutics (FDMT) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Management expects cash and collaboration payments to cover operations at least into the second half of 2028, beyond planned 2027 trial results.
SEC Filings
The institutional holder reported 2,469,425 common shares in a disclosure covering September 30, 2026.
SEC Filings
The 4SIGHT trial targets 514 patients with diabetic macular edema, backed by FDA advanced therapy designation for 4D-150.